Type of non Hodgkin's lymphoma-Mantle cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor

Evaluating SCR chemotherapy for patients with non-Hodgkin’s lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...

Read More

Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy

Posted by on Jun 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...

Read More

Managing side effects of ibrutinib treatment

Posted by on Jun 23, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them.  Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness, and...

Read More

Evaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma

Posted by on Jun 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...

Read More

Evaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...

Read More

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT).  This study concluded that the graft-versus-lymphoma effect leads to...

Read More

Searching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma lose...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients.  Some background Mantle cell...

Read More

Looking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...

Read More

Evaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...

Read More

Predicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...

Read More